Investors

<p>Surfer woman with longboard surfboard at Famara beach in Lanzarote Canary Islands</p>

Welcome to Mendus’ Investor Relations page. Mendus is listed on NASDAQ Stockholm under the ticker symbol IMMU. You will find all relevant information on the Mendus share in our Investors section.

Letter from the CEO

First steps taken towards late-stage development of vididencel

In the first quarter of 2024, Mendus made significant progress with its lead program vididencel in acute myeloid leukemia (AML).

To read the full letter from the CEO, please click here.

Update on Vididencel Program – Webcast and On-Site Event

Mendus provided an update on its lead program vididencel on Tuesday, June 27, 2023. The update took place in an online event and, separately, on-site at the company’s headquarters in Stockholm, Sweden.

The replay of the online event is accessible via the link below.

Vididencel Development Update – Webcast Replay

ASH 2022 Webcast

Watch the replay

 

Mendus KOL Event – November 2022

Watch the replay

 

Latest press releases

Mendus announces collaboration with Institut Bergonié to study ilixadencel in soft tissue sarcomas

Press ReleaseStockholm, Sweden, July 23, 2024Mendus AB (“Mendus” publ; IMMU.ST) announces that it has entered into a collaboration with Institut Bergonié, a leading cancer center in Bordeaux, France to study the Mendus’ intratumoral immune primer ilixadencel in soft tissue sarcomas as
Learn more
Regulatory Release

Change in number of shares and votes in Mendus AB (publ)

Press ReleaseStockholm, Sweden, June 28, 2024As previously announced, the Annual General Meeting of Mendus AB (publ) (“Mendus”) on May 17, 2024, resolved on a reverse share split, whereby twenty (20) existing shares were consolidated into one (1) new share.As a result thereof, the number of
Learn more

Events

Interview with Erik Manting

CEO Erik Manting talks about the latest data presented at EHA demonstrating the link between functional immune responses and long-term survival in AML patients treated with Mendus lead product vididencel
Learn more

Executive interview with Erik Manting, CEO

CEO Erik Manting talks about the company’s lead product vididencel and additional pipeline programs in an interview with Edison’s Soo Romanoff
Learn more

Contact

Telephone

+46 (0)8 732 8400

Email

info@mendus.com

<p>Image of old buildings by a dock with boats laying in the water in the foreground.</p>

Head Office

Västra Trädgårdsgatan 15
111 53 Stockholm
Sweden

<p>City image from a walkway, with a church and tall buildings in the background.</p>

R&D Offices

Emmy Noetherweg 2K
2333 BK Leiden
The Netherlands

<p>Overview image of a city, shot in low sunlight from a far distance.</p>

Gothenburg Office

Mendus C/O AstraZeneca BioventureHub
Pepparedsleden 1
431 83 Mölndal
Sweden

News & events

At Mendus, we share a strong commitment to improve the lives of people with cancer.

News & Events